Sarb Shergill
Senior author of the 2021 report of resTORbio's phase 2b and phase 3 trials of the mTOR inhibitor RTB101 to protect older adults from respiratory infections
resTORbio, Boston (PubMed affiliation, 2021, at the time of the study) · current position not confirmed
The immune system weakens with age, and the idea tested here was that blocking mTOR could improve immune function in older adults. MAN2021, published in Lancet Healthy Longevity in 2021 with Sarb Shergill as last author and the authors listed at resTORbio, reports two large tests of that idea with RTB101, a drug that blocks mTOR, taken once a day for 16 weeks by adults aged 65 and over.
In the phase 2b trial (652 people), fewer people on 10 mg had a laboratory-confirmed respiratory infection than on placebo (19% against 28%), but this came from a pooled analysis not corrected for multiple testing, and the corrected analysis was not significant. The phase 3 trial (1,024 people) used a different main endpoint agreed with the FDA, illness with or without a lab test, and found no difference (26% against 25%). Blood tests in both trials still showed more antiviral genes switched on. For readers, the lesson is that a promising biological signal in older people did not turn into fewer illnesses in the larger trial.
PubMed lists only this paper for Sarb Shergill, with the affiliation resTORbio, Boston. No official biography was found, so the role at the company and the current position could not be confirmed.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2021 | H | Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials MAN2021 Last author of the report of the RTB101 phase 2b and phase 3 trials in adults over 65; phase 3 showed no reduction in respiratory illness. |
Co-authors in the Atlas 2
People with a profile here who share at least one study with Sarb Shergill.
ShowHide
- Dean Quinn Clinical trial investigator at P3 Research in Wellington, New Zealand, who was a co-author of the resTORbio trials that tested low-dose mTOR inhibitors to strengthen immunity in older adults
- Joan B. Mannick Ran early clinical trials of low-dose mTOR inhibitors in older adults, which improved their response to flu vaccination and, in a phase 2a trial, their rate of self-reported infections; a larger phase 3 trial of RTB101 (2021) did not confirm a reduction in respiratory illness. She led this work first at Novartis and then at resTORbio
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.